secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001079973-25-001707
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance
--------------------------------------------------------------------------------

- Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.
- Adjusted EBITDA improved to $(3.5)M from $(8.2)M; diluted EPS $(0.14) vs $(0.18) loss per share.
- Retail pharmacy revenue $75.9M, set fill records, contributed $12.8M gross profit.
- Fee-for-service revenue grew 13% YoY on organic growth in Florida and Oregon.
- Full year 2025 guidance raised (specific figures not disclosed in filed excerpt).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325001707/0001079973-25-001707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997325001707/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-25-001707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer